Market Cap (In KRW)
317.7 Billion
Revenue (In KRW)
17.06 Billion
Net Income (In KRW)
-19.1 Billion
Avg. Volume
355.2 Thousand
- Currency
- KRW
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 8280.0-32750.0
- PE
- -
- EPS
- -
- Beta Value
- 0.699
- ISIN
- KR7226950004
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Dong-Ki Lee Ph.D.
- Employee Count
- -
- Website
- http://www.olixpharma.com
- Ipo Date
- 2018-07-18
- Details
- OliX Pharmaceuticals, Inc., a clinical stage biotechnology company, focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company's products pipeline includes OLX101 for skin scar; OLX102 for skin whitening; OLX103, an atopic dermatitis product; OLX104 for hair loss; OLX105, an anti-wrinkle product; and OLX106 for diabetic foot ulcer. Its products pipeline also comprise OLX301 for age-related macular degeneration retinal fibrosis; OLX304 for retinitis pigmentosa; OLX201 for lung fibrosis; OLX202 for asthma; OLX203 for influenza; OLX401 for neuropathic pain; OLX701 for liver fibrosis; and OLX701 for cancer immunotherapy. The company has a collaboration agreement with Théa to develop SiRNA therapeutics for ophthalmic diseases; and a research collaboration with PCI Biotech Holding ASA. OliX Pharmaceuticals, Inc. was founded in 2010 and is based in Suwon, South Korea.
More Stocks
-
JDW
-
1930
-
095660NEOWIZ
095660
-
ARAMIAramis Group SAS
ARAMI
-
EVLIEvli Oyj
EVLI
-
EXE
-
ORAGFMonarca Minerals Inc.
ORAGF
-
HAMPHampidjan Hf.
HAMP